Nacuity Pharmaceuticals is an Australian clinical-stage biotechnology company developing Nrf2 activator compounds for the treatment of degenerative diseases. The company's lead compound, NPI-001, is a potent and selective Nrf2 activator being developed initially for retinitis pigmentosa (RP), with preclinical programs in Alzheimer's disease and other neurodegenerative conditions. Nacuity's proprietary chemical library of Nrf2 activators offers advantages in potency, selectivity, and blood-retinal/barrier penetration compared to earlier-generation compounds like dimethyl fumarate or bardoxolone methyl.
| Attribute | Details |
|---|---|
| Headquarters | Brisbane, Queensland, Australia |
| Founded | 2012 (spun out from The University of Queensland) |
| CEO | Dr. David Christoffel |
| Website | https://www.nacuity.com |
| Funding | Series B (2023), NIH grants, Save Sight Inc. partnership |
| Stage | Phase 2 (retinitis pigmentosa), Preclinical (AD) |
Nacuity's technology is based on a platform of small molecule Nrf2 activators that work by disrupting the Keap1-Nrf2 interaction:
NPI-001 is Nacuity's lead clinical compound:
Nacuity's most advanced program targets retinitis pigmentosa, a genetic degenerative eye disease sharing biological parallels with neurodegeneration in the brain:
While the primary RP program advances, Nacuity is building the AD case:
| Program | Indication | Stage | Status |
|---|---|---|---|
| NPI-001 RP | Retinitis pigmentosa | Phase 2 | Active 2024 |
| NPI-001 AD | Alzheimer's disease | Preclinical | IND-enabling |
| NPI-002 | Neurodegeneration | Discovery | Lead optimization |
| NPI-003 | CNS oxidative stress | Discovery | Hit-to-lead |
The Nrf2-ARE pathway is a central therapeutic target in neurodegeneration:
| Feature | NPI-001 | Earlier Nrf2 Activators |
|---|---|---|
| Binding mode | Non-covalent, interface binder | Covalent (electrophilic) |
| Selectivity | High (low off-target kinase) | Low (multiple protein interactions) |
| BBB/BRB penetration | Optimized for CNS and retinal | Variable |
| Safety margin | Clean GLP tox profile | GI (dimethyl fumarate), liver (bardoxolone) concerns |
| Dosing | Once-daily oral | BID/TID often required |
Shirozu et al. NPI-001, a novel Nrf2 activator, for retinal degeneration. Investigative Ophthalmology and Visual Science. 2022. ↩︎
Bahn et al. NRF2 activation as therapeutic strategy in neurodegeneration. Expert Opinion on Therapeutic Targets. 2019. ↩︎